Men who suffer from migraines are at increased risk for cardiovascular events, according to researchers. The new findings follow similar reports that women with migraines are at higher risk for cardiovascular disease.
Men who suffer from migraines are at increased risk for cardiovascular events, according to researchers. The new findings follow similar reports that women with migraines are at higher risk for cardiovascular disease.
"This does not mean that people with migraines should panic," said Tobias Kurth, MD, ScD, associate epidemiologist at Brigham and Women's Hospital, Boston, Mass., and assistant professor of medicine at Harvard Medical School. Dr. Kurth led the study team that produced both findings.
"We do not know how or why migraines are associated with increased cardiovascular risk," Dr. Kurth said at a press briefing on Tuesday afternoon. "Physicians and patients with migraine should pay even more attention to traditional cardiovascular risk factors such as high blood pressure, diabetes, cholesterol, smoking, and obesity."
Data from the Physicians' Health Study, which began in 1982, demonstrated that men who reported migraine had a 24% increased risk of all cardiovascular events. The increased risk was driven largely by a 42% increase in the risk of myocardial infarction.
At the beginning of the study, men with migraines were found to have a slightly higher prevalence of hypertension and hypercholesterolemia. Analysis of more than 15 years of health data controlled for both of these pre-existing factors, Dr. Kurth said.
The data are similar to findings from the Women's Health Study. The major difference is that increased cardiovascular risk in women is associated with migraine aura, the visual and neurologic disturbances that frequently precede a migraine attack. The Physician's Health Study did not question male subjects about aura because when the study was designed, researchers were not yet aware of the relationship between migraine and CVD.
"This study and the study in women support the hypothesis that migraine is associated with heart disease," Dr. Kurth said. "The mechanism behind the association is not at all clear. Suspected mechanisms include an increase in thrombolytic factors and inflammatory factors."
He added: "The reality is that we don't really know. Physicians should continue to emphasize modifying other risk factors with their patients."
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Advisory Committee Votes Down Sotagliflozin in Type 1 Diabetes and CKD
November 1st 2024Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic levels in adults with type 1 diabetes and chronic kidney disease. The agency’s goal date is Dec. 20, 2024.
Read More
ICER Gives Cell Therapy for Post-Transplant Complications High Rating
Published: October 31st 2024 | Updated: October 31st 2024ICER has given tabelecleucel a rating of A, indicating the T cell therapy for Epstein-Barr virus related post-transplant lymphoproliferative disease has a high certainty of substantial net health benefit and would be cost-effective if priced between $143,900 and $273,700.
Read More